The trajectory of companies tied to the drug's past presents a complex investment scenario . While the initial boom generated substantial gains, generic competition have significantly eroded revenue. Investing in connected pharmaceutical companies now requires a thorough assessment of proprietary safeguards, evolving healthcare trends , and the pot